MICA triggering signal for NK cell tumor lysis is counteracted by HLA‐G1‐mediated inhibitory signal
Open Access
- 13 May 2002
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 100 (1) , 63-70
- https://doi.org/10.1002/ijc.10460
Abstract
MICA, a highly glycosylated membrane‐anchored cell–surface MHC Class I‐related chain, has recently been reported to activate NK cell cytolytic responses in epithelial tumors. Tumor cells may escape from NK lysis by counteracting NK cytotoxicity activating signals with inhibitory ones. Among the molecules that mediate an NK inhibitory signal, HLA‐G1, a non‐classical MHC Class I antigen, is of particular interest. HLA‐G1 is ectopically expressed in various tumors, including melanoma and constitutes the major NK inhibitory ligand in the M8 melanoma cell line when coexpressed with HLA‐A, ‐B, ‐C and ‐E molecules. We have evaluated the balance between 2 powerful signals that affect NK cell tumor lysis, one inhibitory and the other one activating, respectively HLA‐G1 and MICA. For this purpose, we transfected the M8 melanoma cell line, which spontaneously expresses MICA, with HLA‐G1 cDNA, using it as a target for the NKL effector. We carried out cytotoxicity assays, using antibodies that disrupt interactions between the MICA and HLA‐G1 ligands and their respective NK effector counterparts, the NKG2D activating and ILT2 inhibitory receptors. Results showed that 1) MICA expressed in the M8 melanoma cell line triggered NK cell tumor lysis and 2) HLA‐G1 coexpression mediated the inhibition of NK cytotoxicity by mitigating the MICA activating signal. HLA‐G1 expression in a tumor cell line in which MICA is switched on would therefore appear to be a powerful way to turn off NK cells, supporting the emerging idea that the balance between positive and negative NK cytolysis signals critically influences tumor progression.Keywords
This publication has 65 references indexed in Scilit:
- Human Leukocyte Antigen G Up-Regulation in Lung Cancer Associates with High-Grade Histology, Human Leukocyte Antigen Class I Loss and Interleukin-10 ProductionThe American Journal of Pathology, 2001
- Soluble human leukocyte antigen-G serum level is elevated in melanoma patients and is further increased by interferon-? immunotherapyCancer, 2001
- Human NK-cell receptorsImmunology Today, 2000
- Expression analysis of classic and non-classic HLA molecules before interferon alfa-2b treatment of melanomaThe Lancet, 2000
- Paired inhibitory and triggering NK cell receptors for HLA class I moleculesHuman Immunology, 2000
- Crystal Structure of the MHC Class I Homolog MIC-A, a γδ T Cell LigandImmunity, 1999
- p46, a Novel Natural Killer Cell–specific Surface Molecule That Mediates Cell ActivationThe Journal of Experimental Medicine, 1997
- The host—tumor immune conflict: from immunosuppression to resistance and destructionImmunology Today, 1997
- Implications for immunosurveillance of altered HLA class I phenotypes in human tumoursImmunology Today, 1997
- Inhibitory MHC class I receptors on NK cells and T cellsImmunology Today, 1996